Proshares Ultra Nasdaq Etf Profile
| BIB Etf | USD 59.65 1.03 1.76% |
Performance0 of 100
| Odds Of DistressLess than 9
|
ProShares Ultra is trading at 59.65 as of the 28th of November 2024, a 1.76% up since the beginning of the trading day. The etf's open price was 58.62. ProShares Ultra has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for ProShares Ultra Nasdaq are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the funds investment objective. Ultra Nasdaq is traded on NASDAQ Exchange in the United States. More on ProShares Ultra Nasdaq
Moving against ProShares Etf
ProShares Etf Highlights
| Thematic Ideas | (View all Themes) |
| Business Concentration | Sector ETFs, Health Care ETFs, Trading--Leveraged Equity, ProShares (View all Sectors) |
| Issuer | ProShares |
| Inception Date | 2010-04-06 |
| Benchmark | Nasdaq Biotech Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 77.28 Million |
| Average Trading Valume | 14,854.6 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | J.P. Morgan Investor Services Co. |
| Advisor | ProShare Advisors LLC |
| Custodian | JPMorgan Chase Bank, N.A. |
| Distributor | SEI Investments Distribution Co. |
| Portfolio Manager | Michael Neches, Tarak Dave |
| Transfer Agent | JPMorgan Chase Bank, N.A. |
| Fiscal Year End | 31-Dec |
| Exchange | NASDAQ |
| Number of Constituents | 244 |
| Market Maker | Virtu Financial |
| Total Expense | 1.15 |
| Management Fee | 0.75 |
| Country Name | USA |
| Returns Y T D | 3.54 |
| Name | ProShares Ultra Nasdaq Biotechnology |
| Currency Code | USD |
| Open Figi | BBG000QMBZX6 |
| In Threey Volatility | 34.57 |
| 1y Volatility | 35.28 |
| 200 Day M A | 59.9765 |
| 50 Day M A | 62.2334 |
| Code | BIB |
| Updated At | 27th of November 2024 |
| Currency Name | US Dollar |
ProShares Ultra Nasdaq [BIB] is traded in USA and was established 2010-04-06. The fund is classified under Trading--Leveraged Equity category within ProShares family. The entity is thematically classified as Sector ETFs. ProShares Ultra Nasdaq currently have 88.04 M in assets under management (AUM). , while the total return for the last 3 years was -11.3%.
Check ProShares Ultra Probability Of Bankruptcy
Geographic Allocation (%)
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on ProShares Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding ProShares Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as ProShares Ultra Nasdaq Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top ProShares Ultra Nasdaq Etf Constituents
| KROS | Keros Therapeutics | Stock | Health Care | |
| BBIO | BridgeBio Pharma | Stock | Health Care | |
| VIR | Vir Biotechnology | Stock | Health Care | |
| ETNB | 89bio Inc | Stock | Health Care | |
| LXRX | Lexicon Pharmaceuticals | Stock | Health Care | |
| ITCI | Intracellular Th | Stock | Health Care | |
| TWST | Twist Bioscience Corp | Stock | Health Care | |
| TVTX | Travere Therapeutics | Stock | Health Care |
ProShares Ultra Top Holders
| HCMGX | Hcm Tactical Growth | Mutual Fund | Large Growth | |
| HCMDX | Hcm Tactical Growth | Mutual Fund | Large Growth | |
| HCMIX | Hcm Tactical Growth | Mutual Fund | Large Growth | |
| HCMSX | Hcm Tactical Growth | Mutual Fund | Large Growth |
ProShares Ultra Nasdaq Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ProShares Ultra. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.10) |
ProShares Ultra Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ProShares Ultra Nasdaq. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
The market value of ProShares Ultra Nasdaq is measured differently than its book value, which is the value of ProShares that is recorded on the company's balance sheet. Investors also form their own opinion of ProShares Ultra's value that differs from its market value or its book value, called intrinsic value, which is ProShares Ultra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProShares Ultra's market value can be influenced by many factors that don't directly affect ProShares Ultra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProShares Ultra's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProShares Ultra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProShares Ultra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.